Abstract 563P
Background
Osimertinib, the standard first-line therapy for EGFR-mutated (EGFRm) advanced non-small cell lung cancer (NSCLC), preliminarily demonstrated similar clinical effectiveness to the landmark FLAURA study in the prospective, non-interventional, real-world FLOURISH study at the first interim analysis. This report presents an updated effectiveness and safety results.
Methods
A total of 500 patients were recruited into the FLOURISH study from 22 sites in China between July 27, 2020, and April 27, 2022. This analysis included 460 patients who met the eligibility criteria and received at least one dose of osimertinib after enrolment and without protocol violation into the full analysis set (FAS) for effectiveness analysis, and 495 patients who received at least one dose of osimertinib after enrolment into the safety set (SS). The data cut-off date was June 30, 2023.
Results
Of the 460 patients in FAS, the median age was 64.1 years (range: 27-88), 62.4% were female, 64.8% had comorbidities, 35.0% with CNS metastases, and 98.7% in stage IIIB-IV. The objective response rate (ORR) was 61.8% (238/385), and disease control rate (DCR) was 96.1% (370/385) in evaluable patients. With a median follow-up of 18.0 months, the 1-year progression-free survival (PFS) and 1-year overall survival (OS) rate was 79.6% (95%CI: 75.0%-83.3%) and 90.0% (95%CI: 86.8%-92.5%), respectively. In patients with CNS metastases, ORR was 63.8% (90/141), DCR was 95.0% (134/141), 1-year PFS rate was 78.9%, and 1-year OS rate was 90.1%. Moreover, patients with exon 19 deletion (n=235) had higher 1-year PFS (84.2% vs. 75.0%) and 1-year OS (93.4% vs. 86.8%) rates than patients with exon 21 L858R (n=212). Among the 495 patients in SS, 195 patients (39.4%) experienced adverse events (AEs), with 18(3.6%) of grade ≥3. AEs leading to dose interruption or discontinuation were reported in 3 (0.6%) and 12(2.4%) patients, respectively.
Conclusions
The FLOURISH study showed consistence with FLAURA in terms of effectiveness of first-line osimertinib for Chinese patients with advanced EGFRm-NSCLC in real world setting. No new safety signals were observed. The follow-up is still ongoing and the final analysis is expected in future.
Clinical trial identification
NCT04391283.
Editorial acknowledgement
Legal entity responsible for the study
Guangdong Association of Clinical Trials.
Funding
AstraZeneca China.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
592P - Treatment patterns and outcomes in patients with advanced non-small cell lung cancer with MET exon 14 skipping alterations in China
Presenter: Hanxiao Chen
Session: Poster Display
Resources:
Abstract
593P - MET TKIs in Asian patients (pts) with MET exon 14 skipping NSCLC: A matching-adjusted indirect comparison (MAIC)
Presenter: E-e Ke
Session: Poster Display
Resources:
Abstract
594P - The treatment pattern and clinical outcome in NSCLC patients with MET alteration: A retrospective real-world analysis in China
Presenter: Yongfeng Yu
Session: Poster Display
Resources:
Abstract
595P - Durable efficacy of zenocutuzumab, a HER2 x HER3 bispecific antibody, in advanced NRG1 fusion-positive (NRG1+) non-small cell lung cancer (NSCLC)
Presenter: Koichi Goto
Session: Poster Display
Resources:
Abstract
596P - Repotrectinib in patients (pts) from Asia and China with ROS1 fusion-positive (ROS1+) non-small cell lung cancer (NSCLC): Results from the phase I/II TRIDENT-1 trial
Presenter: Ross Soo
Session: Poster Display
Resources:
Abstract
597TiP - A phase I/II study to evaluate the safety and anti-tumor activity of JIN-A02 in patients with EGFR TKI-refractory, EGFR-mutant advanced NSCLC
Presenter: Sun Min Lim
Session: Poster Display
Resources:
Abstract
598TiP - Exploration of aumolertinib in first-line treatment for advanced non-small cell lung cancer patients of performance status 3 with EGFR mutations (19del and L858R)
Presenter: Haiyi Deng
Session: Poster Display
Resources:
Abstract
599TiP - A prospective study of savolitinib plus docetaxel in pretreated EGFR/ALK/ROS1/METex14m-wildtype advanced NSCLC patients with MET overexpression (FirstMET)
Presenter: Shuting Zhan
Session: Poster Display
Resources:
Abstract
600TiP - Phase III study of telisotuzumab vedotin (Teliso-V) vs docetaxel in pretreated c-Met overexpressing EGFR wildtype (WT) non-squamous (NSQ) locally advanced/metastatic non-small cell lung cancer (a/mNSCLC)
Presenter: Junko Tanizaki
Session: Poster Display
Resources:
Abstract
601P - Pembrolizumab in patients of Chinese descent with microsatellite instability-high/mismatch repair deficient advanced solid tumors: KEYNOTE-158
Presenter: Xiaohua Wu
Session: Poster Display
Resources:
Abstract